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EDITORIAL
ADC  normalization:  A  promising  research  track  for
diffusion-weighted  MR  imaging  of  the  abdomen
Diffusion-weighted  magnetic  resonance  imaging  (DW-MRI)  is  a  technique  that  helps
quantify  the  movement  of  water  molecules  at  a  cellular  level.  DW-MRI  is  sensitive  to  the
thermally  driven  random  motion  of  water  protons,  which  is  dependent  of  their  interactions
with  cell  membranes  and  macromolecules.  Consequently,  the  diffusion  of  water  in  tissues
reﬂects  at  various  degrees  a  combination  of  tissue  cellularity,  tortuosity  of  extracellular
spaces,  integrity  of  cell  membranes  and  viscosity  of  ﬂuids.  When  present,  high  cellularity,
necrosis,  inﬂammation  and  ﬁbrosis  substantially  alter  the  diffusion  properties  of  water
and,  thus,  affect  the  returned  signal.
To  date,  two  models  have  been  applied  to  abdominal  imaging  using  DW-MRI  [1].  One  is
the  mono-exponential  model,  which  is  the  most  commonly  used  in  daily  practice.  The  other
one  is  a  bi-exponential  model,  which  accounts  for  separating  tissue  diffusivity  and  tissue
microcapillary  perfusion.  The  bi-exponential  model  is  based  on  the  intravoxel  incoherent
motion  (IVIM)  theory  that  was  introduced  by  Le  Bihan  et  al.  as  a  joint  method  to  measure
perfusion  and  diffusion  [1].  Multiple  b  value  IVIM  models  (i.e.,  more  than  10  b  values)  based
on  the  bi-exponential  ﬁtting  theory  are  complex  and  time  consuming  because  of  a  long
post-processing  time  and  show  high  degrees  of  variability  and  reproducibility,  especially
for  the  perfusion  related  parameter  D*  [2,3].  Consequently,  bi-exponential  post-processing
using  multiple  b  values  is  not  routinely  performed  although  it  is  being  widely  evaluated  in
research  [3—7].
Dramatic  advances  in  image  quality  during  recent  years,  mainly  due  to  substantial
reﬁnements  in  hardware  and  coil  systems,  have  made  DW-MRI  a  promising  technique  for
the  detection  and  characterization  of  a  wide  range  of  pathologic  condition  in  the  abdomen
and  pelvis  [8—17]. The  implementation  of  ultrafast  MRI  techniques,  such  as  echo-planar
imaging  (EPI)  combined  with  parallel  imaging  using  multicoil  state-of-the-art  MRI  scanners,
has  made  DW-MRI  of  the  abdomen  a  feasible  option  in  clinical  practice.  Scan  acquisitions
can  be  performed  relatively  quickly,  does  not  require  administration  of  gadolinium-chelate
and  enables  qualitative  and  quantitative  assessment  of  tissue  diffusivity  (diffusion  coefﬁ-
cients).  Beyond  detection  and  characterization,  DW-MRI  shows  also  promise  for  monitoring
abdominal  cancer  response  to  therapy  [9].  Although  DW-MRI  has  received  considerable
attention  and  has  been  subjected  to  marked  developments  in  the  area  of  liver  disease,  by
contrast  less  has  been  made  regarding  the  pancreas.  One  reason  may  be  that  the  pancreas
is  a  deep,  central  and  relatively  small  organ  in  the  abdomen,  far  from  coil  elements  so
that  DW-MRI  of  this  organ  may  be  rendered  difﬁcult  because  of  signal  loss  by  comparison
with  the  liver.  However,  a careful  selection  of  technical  parameters  for  DW-MRI  image
acquisition  may  contribute  to  increase  the  pancreatic  signal.  Signal-to-noise  ratio  may  be
improved  by  using  a  minimum  TE,  by  increasing  the  number  of  averages,  and  decreasing
bandwidth.  Another  reason  may  be  that  encouraging  results  achieved  with  DW-MRI  in  the
liver  are  not  mirrored  by  those  obtained  in  the  pancreas.
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As  illustrated  recently,  one  major  limitation  of  DW-MR
maging  is  the  difﬁculty  to  differentiate  between  pancre-
tic  adenocarcinoma  and  mass-forming  pancreatitis  because
f  overlap  in  ADC  values  [18,19].  Differentiation  between
ass-forming  pancreatitis  and  pancreatic  cancer  with  con-
entional  ADC  measurement  is  not  so  straightforward
ecause  of  inconsistencies  and  conﬂicting  results  between
ublished  studies  [20].  Some  studies  reported  greater  ADC
alues  for  mass-forming  pancreatitis  than  for  pancreatic
ancers,  others  reported  greater  ADC  values  for  pancre-
tic  cancers  than  for  mass-forming  pancreatitis  whereas
thers  did  not  ﬁnd  any  signiﬁcant  differences  in  ADC  val-
es  between  these  two  conditions.  One  reason  may  be  that
ass-forming  pancreatitis  may  contain  variable  proportions
f  ﬁbrosis  and  inﬂammation,  which  may  explain  variations
mong  studies  and  overlap  in  ADC  values  between  mass-
orming  pancreatitis  and  pancreatic  cancers  [19].
The  preliminary  results  by  Barral  et  al.  suggest  that  nor-
alized  ADC  helps  characterize  focal  pancreatic  lesions  and
urther  discriminate  between  pancreatic  cancers  and  mass-
orming  pancreatitis  [20].  In  their  study,  the  use  of  the
onventional  ADC  was  less  discriminating  because  of  marked
verlap  in  ADC  values  between  these  two  entities,  and  this
as  consistent  with  the  results  of  other  researchers  [5]. The
esults  of  their  study  show  that  ADC  measurements  using  a
ormalized  ADC  is  more  discriminating  than  the  more  com-
on  ADC  to  differentiate  between  focal  pancreatic  lesions,
nd  more  speciﬁcally  between  malignant  pancreatic  tumors
nd  mass-forming  pancreatitis  [20].
The  concept  of  normalized  ADC  using  a  reference  organ
s  relatively  new  and  has  been  found  to  improve  repro-
ucibility  and  reduce  variability  in  ADC  measurement  of  the
epatic  parenchyma  and  focal  liver  lesions  at  1.5-T  [21,22].
DC  normalization  has  been  deﬁned  already  in  the  abdomen
sing  the  spleen  as  a  reference  organ  but  there  is  no  def-
nite  consensus  about  the  most  appropriate  organ  to  date
21,22].  One  advantage  of  using  the  adjacent  organ  (hep-
tic  parenchyma  or  pancreatic  parenchyma)  instead  of  the
pleen  as  a  reference  organ  is  that  measurements  are  made
asier  with  ROIs  used  for  calculation  placed  on  the  same
evel  of  slice  and  because  it  is  assumed  that  the  adjacent
arenchyma  is  subjected  to  the  same  ﬁeld  heterogeneity
nd  susceptibility  effects  than  the  lesion.  As  a  limitation,
owever,  the  apparently  healthy  adjacent  parenchyma  used
or  normalization  may  be  involved  at  some  degrees  by  an
nderlying  disease.  This  limitation  may  apply  more  particu-
arly  in  the  liver  that  may  be  involved  by  steatosis  or  ﬁbrosis
hat  affect  the  ADC  value  [23].
In  the  pancreas,  normalized  ADC  has  been  deﬁned  using
he  adjacent  pancreas  as  a  reference  organ  [20]. Thus,  nor-
alized  ADC  is  deﬁned  as  the  ratio  of  focal  pancreatic
esion  ADC  to  apparently  normal  adjacent  pancreas  ADC.
or  the  above-mentioned  reasons,  normalization  should  thus
ecrease  the  potential  inﬂuence  of  artifacts  on  ADC  cal-
ulation.  More  speciﬁcally,  regarding  the  pancreas,  ADC  is
imilar  in  the  different  pancreatic  segments  and  a disease
n  the  upstream  pancreas  (i.e.,  body  and  tail)  does  not  cause
igniﬁcant  alteration  in  the  ADC  value  of  the  pancreatic
arenchyma  downstream  (i.e.,  in  pancreatic  head)  [24,25].
inally,  in  theory,  the  ADC  of  the  normal  parenchyma  should
ot  change  with  time  or  treatment  whereas  tumor  necrosis
hould  increase  the  ADC  of  the  lesion.  However,  in  ﬁbrousEditorial
ancreatic  parenchyma  an  overlap  between  tumor  (such
s  pancreatic  ductal  adenocarcinomas)  and  adjacent  tissue
ay  bafﬂe  ADC  normalization.  In  addition,  as  regards  to  liver
ehavior,  fatty  inﬁltration  of  the  pancreas  may  occur  during
hemotherapy  or  in  patients  with  underlying  chronic  disease
nd  increases  ADC  value  [26,27].  Thus,  changes  in  pancre-
tic  parenchyma  during  treatment  while  absence  of  tumor
esponse  or  tumor  necrosis  may  result  in  misinterpretation
f  normalized  ADC.  Of  note,  return  to  normal  value  of  nor-
alized  ADC  could  obscure  tumor  response  and  a  decrease
f  normalized  ADC  may  erroneously  be  interpreted  as  tumor
rogression.
In  conclusion,  to  limit  the  possible  inﬂuence  of  endoge-
ous  and  exogenous  parameters  on  the  resulting  ADC  value,
arral  et  al.  have  used  a  normalized  ADC  to  improve  charac-
erization  of  pathologic  conditions  with  DW-MRI  [20].  This
pproach  has  been  evaluated  for  the  characterization  of
ocal  pancreatic  lesions  only  in  this  study  so  far,  so  that
here  is  no  strong  evidence  for  a  deﬁnite  recommendation.
n  addition,  Barral  et  al.  have  restricted  their  investigation
o  a  limited  number  of  pathologic  conditions  of  the  pan-
reas  [28].  However,  in  light  of  their  preliminary  results,
t  can  be  reasonably  assumed  that  ADC  normalization  is  a
romising  tool  to  improve  accuracy  of  ADC  measurement
nd  diagnostic  performances.  As  a  limitation,  potential  pit-
alls  such  as  pancreatic  ﬁbrosis  and  fatty  involution  should
e  considered  when  using  normalized  ADC.  Currently,  one
ajor  limitation  of  DW-MRI  is  the  inability  to  distinguish
etween  MFP  and  ductal  adenocarcinoma  due  to  an  overlap
f  ADC  values  that  mirrors  an  overlap  in  histological  ﬁndings.
he  lack  of  standardization  in  DW-MRI  (including  acquisition
rotocol  and  signal  analysis)  is  an  important  limitation  for  a
alid  inter-study  comparison.  To  overcome  these  limitations,
ormalized  ADC  along  with  IVIM  models  can  be  considered
uture  research  tracks  because  technological  innovation
ontinues  to  improve  the  quality  of  clinical  DW-MRI  and  more
eﬁned  data  processing  systems  are  now  available.
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